FranceFrance

Sanofi's MS-drug Alemtuzumab meets first primary goal

12.07.2011

French drug maker Sanofi SA announced mixed results of a late-stage trial of multiple sclerosis drug Lemtrada. The two-year study CARE-MS I is the first of two randomised, Phase 3 clinical trials comparing Sanofi's alemtuzumab to Rebif. The CARE-MS I study incorporated 581 patients with relapsing-remitting multiple sclerosis who had not had prior treatment for their illness and showed that Lemtrada helped patients more than Rebif, Merck KGaA's established multiple sclerosis therapy. The product cut relapse rates by 55 percent over two years compared with Rebif Sanofi said in a statement on Monday. But Lemtrada failed on the second goal; statistically, it is not better than Rebif in helping stave off disability for the duration of the test. Sanofi's shares not unexpectedly fell after the announcement. Another Phase 3 clinical trial, CARE-MS II, is currently underway, evaluating Lemtrada against Rebif in relapsing-remitting multiple sclerosis patients who have relapsed while on therapy. The medicine’s prospects were at the heart of the Genzyme takeover talks this year. Cambridge, Massachusetts-based Genzyme was projecting peak annual sales of as much as $3.5 billion, saying Lemtrada was likely to become its bestseller. Sanofi said in October that analysts’ estimates of about $700 million were a valuation “probably closer to the reality of the product.” Sanofi expects to file the drug for U.S. and European Union approval in multiple sclerosis in early 2012 and has been granted fast track designation by the U.S. FDA. Sanofi has time. Cash is not the problem. On Monday the French drugmaker revealed it was selling its Dermik dermatology business to Canada's Valeant Pharmaceuticals for $425 million.

FranceFrance

10.06.2011

Paris/Berlin – Germany and France are establishing a new form of cross-border cooperation in the life sciences. The French public health research institute Inserm and the German Helmholtz Association have agreed to build up joint...

FranceFrance

10.05.2011

Pomacle/Paris/Minneapolis – French/US firm BioAmber Inc. has raised US$45 million dollars in a Series B financing led by Paris-based private equity firm NAXOS Capital Partners and with participation of BioAmber's largest...

FranceFrance

02.05.2011

Paris - Sanofi-Aventis was reminded that steady income flows in the pharma buisness are a thing of the past. The French drugmaker saw its earnings fall by nearly 30 percent in the first quarter, as low swine flu vaccine sales...

FranceFrance

21.04.2011

Sophia Antipolis – French nitric oxide-donating drug specialist NicOx S.A. has withdrawn the EU Marketing Authorization Application (MAA) for ist osteoarthritis candidate naproxcinod (Beprana) after a meeting of the European...

FranceFrance

10.04.2011

Paris – French researchers under Etienne Hirsch from the Pasteur University in Paris have discovered that glucocorticoid receptors (GR) play a pivotal role in inflammation-mediated damage of dopaminergic neurons in the course of...

FranceFrance

04.04.2011

Toulouse – Three French research clusters have earmarked EUR20 million to build a pre-industrial demonstration plant in the area of white biotechnology. The new facility, will test the feasibility of industrial production of 2nd...

FranceFrance

01.04.2011

Toulouse – Three French research clusters have earmarked EUR20m to build a pre-industrial demonstration plant in the area of white biotechnology. The new facility, named Toulouse White Biotech­nology (TWB), will test the...

FranceFrance

01.04.2011

Lyon – Fuelled by governmental support, the French biotech sector experienced a vintage year in 2010, with a second generation of companies now emerging. But according to the Life Science Panorama 2010 survey, released by the...

FranceFrance

18.03.2011

Lille – Biopharmaceutical company Genfit has signed a deal with drug giant Sanofi-Aventis to discover molecules to correct mitochondrial dysfunction associated with metabolic disease. Sanofi will have exclusive worldwide rights...

Displaying results 31 to 40 out of 268

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-france/browse/3/article/sanofis-ms-drug-alemtuzumab-meets-first-primary-goal.html

Events

All Events

Stock list

All quotes

TOP

  • ADDEX3.51 CHF12.14%
  • STRATEC BIOMEDICAL41.09 EUR4.55%
  • MEDIGENE4.00 EUR2.30%

FLOP

  • CYTOS0.18 CHF-5.26%
  • MOLOGEN6.60 EUR-2.22%
  • SANTHERA86.95 CHF-1.92%

TOP

  • PAION3.22 EUR33.6%
  • CO.DON3.14 EUR27.6%
  • FORMYCON8.20 EUR16.3%

FLOP

  • CYTOS0.18 CHF-28.0%
  • EVOTEC3.10 EUR-16.7%
  • MOLOGEN6.60 EUR-12.8%

TOP

  • SANTHERA86.95 CHF2146.8%
  • PAION3.22 EUR238.9%
  • CO.DON3.14 EUR223.7%

FLOP

  • CYTOS0.18 CHF-95.3%
  • MOLOGEN6.60 EUR-44.5%
  • 4SC1.04 EUR-44.4%

No liability assumed, Date: 01.10.2014


Current issue

All issues

Product of the week

Products